Management of adverse events in patients with acute myeloid leukemia in remission receiving oral azacitidine: experience from the phase 3 randomized QUAZAR AML-001 trial

Autor: Farhad Ravandi, Gail J. Roboz, Andrew H. Wei, Hartmut Döhner, Christopher Pocock, Dominik Selleslag, Pau Montesinos, Hamid Sayar, Maurizio Musso, Angela Figuera-Alvarez, Hana Safah, William Tse, Sang Kyun Sohn, Devendra Hiwase, Timothy Chevassut, Francesca Pierdomenico, Ignazia La Torre, Barry Skikne, Rochelle Bailey, Jianhua Zhong, C. L. Beach, Herve Dombret
Jazyk: angličtina
Rok vydání: 2021
Předmět:
Zdroj: Journal of Hematology & Oncology, Vol 14, Iss 1, Pp 1-14 (2021)
Druh dokumentu: article
ISSN: 1756-8722
DOI: 10.1186/s13045-021-01142-x
Popis: Abstract Background Most older patients with acute myeloid leukemia (AML) who attain morphologic remission with intensive chemotherapy (IC) will eventually relapse and post-relapse prognosis is dismal. In the pivotal QUAZAR AML-001 trial, oral azacitidine maintenance therapy significantly prolonged overall survival by 9.9 months (P
Databáze: Directory of Open Access Journals